1425 related articles for article (PubMed ID: 33975397)
1. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
Jia Z; Gong W
J Korean Med Sci; 2021 May; 36(18):e124. PubMed ID: 33975397
[TBL] [Abstract][Full Text] [Related]
2. Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.
Saade C; Gonzalez C; Bal A; Valette M; Saker K; Lina B; Josset L; Trabaud MA; Thiery G; Botelho-Nevers E; Paul S; Verhoeven P; Bourlet T; Pillet S; Morfin F; Trouillet-Assant S; Pozzetto B; On Behalf Of Covid-Ser Study Group
Emerg Microbes Infect; 2021 Dec; 10(1):1499-1502. PubMed ID: 34176436
[TBL] [Abstract][Full Text] [Related]
3. Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.
Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
mBio; 2021 Aug; 12(4):e0114021. PubMed ID: 34465019
[TBL] [Abstract][Full Text] [Related]
4. Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.
Singh J; Samal J; Kumar V; Sharma J; Agrawal U; Ehtesham NZ; Sundar D; Rahman SA; Hira S; Hasnain SE
Viruses; 2021 Mar; 13(3):. PubMed ID: 33803400
[TBL] [Abstract][Full Text] [Related]
5. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants.
Chaqroun A; Hartard C; Schvoerer E
Viruses; 2021 Jun; 13(6):. PubMed ID: 34207378
[TBL] [Abstract][Full Text] [Related]
7. Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.
Wahid M; Jawed A; Mandal RK; Dailah HG; Janahi EM; Dhama K; Somvanshi P; Haque S
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5857-5864. PubMed ID: 34604978
[TBL] [Abstract][Full Text] [Related]
8. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
9. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
10. Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil.
Slavov SN; Patané JSL; Bezerra RDS; Giovanetti M; Fonseca V; Martins AJ; Viala VL; Rodrigues ES; Santos EV; Barros CRS; Marqueze EC; Santos B; Aburjaile F; Neto RM; Moretti DB; Haddad R; Calado RT; Kitajima JP; Freitas E; Schlesinger D; Junior de Alcantara LC; Elias MC; Sampaio SC; Kashima S; Covas DT
J Med Virol; 2021 Dec; 93(12):6782-6787. PubMed ID: 34241897
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS
Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.
Shen X; Tang H; McDanal C; Wagh K; Fischer W; Theiler J; Yoon H; Li D; Haynes BF; Sanders KO; Gnanakaran S; Hengartner N; Pajon R; Smith G; Glenn GM; Korber B; Montefiori DC
Cell Host Microbe; 2021 Apr; 29(4):529-539.e3. PubMed ID: 33705729
[TBL] [Abstract][Full Text] [Related]
13. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
[TBL] [Abstract][Full Text] [Related]
14. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
[TBL] [Abstract][Full Text] [Related]
15. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
[TBL] [Abstract][Full Text] [Related]
16. Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein.
La Rosa G; Mancini P; Bonanno Ferraro G; Veneri C; Iaconelli M; Lucentini L; Bonadonna L; Brusaferro S; Brandtner D; Fasanella A; Pace L; Parisi A; Galante D; Suffredini E
Water Res; 2021 Jun; 197():117104. PubMed ID: 33857895
[TBL] [Abstract][Full Text] [Related]
17. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
18. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
19. Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.
Carreño JM; Alshammary H; Singh G; Raskin A; Amanat F; Amoako A; Gonzalez-Reiche AS; van de Guchte A; Study Group P; Srivastava K; Sordillo EM; Sather DN; van Bakel H; Krammer F; Simon V
EBioMedicine; 2021 Nov; 73():103626. PubMed ID: 34688034
[TBL] [Abstract][Full Text] [Related]
20. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
